Seaport Therapeutics Reports Positive GlyphAllo Data; GlyphAgo Phase 2a Trial Underway

Seaport Therapeutics reported a Q3 2026 net loss of $26.4M, up from $22.5M a year earlier, driven by increased R&D spending. Cash reserves totaled $403.8M, expected to last into 2029. Key clinical updates include positive Phase 1 results for GlyphAllo and the start of a Phase 2a trial for GlyphAgo.

Seaport Therapeutics reported a net loss of $26.4M in Q3 2026, up $3.9M from the prior year. Diluted loss per share was $0.49, compared to $9.43, due to a higher share count. The company is advancing its pipeline, with key trials expected to report results in 2027 and 2028, and anticipates continued operating losses.

Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo TM , showing that GlyphAllo did not impair next-morning driving

PureTech Health's Seaport Therapeutics presented Phase 1 data for GlyphAgo, an anxiety disorder drug candidate, at a congress in Munich. The trial showed a 6.8-fold increase in bioavailability of agomelatine compared to unmodified agomelatine and lower pharmacokinetic variability. Seaport plans to initiate a Phase 2/3 trial in early 2027 and expects topline results from a Phase 2a trial in early 2028.

Seaport Therapeutics (SPTX) presented Phase 1 data for GlyphAgo, an agomelatine prodrug, at the ECNP Congress. The trial showed a 6.8-fold increase in bioavailability and lower variability. Phase 2a results are expected in early 2028. Parent company PureTech Health (PRTC) announced the data.

Seaport Therapeutics reported Phase 1 data for GlyphAgo, showing 6.8x higher bioavailability and 10x lower variability in agomelatine. Phase 2/3 trials for GAD are planned for H1 2027, with Phase 2a ongoing for GAD with sleep disturbance.